BI Asset Management Fondsmaeglerselskab A S reduced its position in CVS Health Corporation by 30.1% during the third quarter, selling 166,058 shares and ending the period with 386,062 shares. The divestiture lowered the investor’s total holding value to $27.54 million, according to the latest Form 13F filed with the Securities and Exchange Commission. This move represents one of the more significant stake reductions among the top institutional holders of the pharmacy operator.

Several hedge funds and asset managers also modified their CVS Health stakes in the same period. Savant Capital LLC raised its share count by 33.5%, acquiring 18,507 additional shares to reach 73,762, valued at $5.56 million. Unison Advisors LLC added 547 shares for a 1.0% increase, bringing its total to 55,411 shares worth $4.18 million. J.W. Cole Advisors Inc. boosted its position by 7.5%, purchasing 1,852 shares to reach 26,407 shares valued at $1.99 million. Envestnet Asset Management Inc. expanded its stake by 2.6%, adding 51,076 shares to total 1,990,902 shares with a value of $150.09 million. Marco Investment Management LLC increased its holdings by 2.4%, adding 1,805 shares for a total of 76,236 shares worth $5.75 million. Overall, institutional and hedge fund ownership represents 80.66% of the company’s outstanding shares.

CVS Health declared and paid a quarterly dividend of $0.665 per share to holders of record as of January 22, representing an annualized payout of $2.66 and a yield of 3.5%. The company’s liquidity ratios stood at a quick ratio of 0.63 and a current ratio of 0.83, while its debt-to-equity ratio was reported at 0.83. These metrics reflect moderate leverage and working capital coverage within its diversified healthcare operations.

A total of nineteen research analysts have assigned buy ratings to CVS Health, with four issuing hold recommendations, producing an average consensus rating of Moderate Buy. The consensus price objective stands at $94.82 per share. Recent analyst actions include JPMorgan Chase & Co. raising its target from $93.00 to $101.00, Barclays lifting its objective from $87.00 to $93.00 and Morgan Stanley boosting its target from $89.00 to $93.00. UBS Group and Cantor Fitzgerald have reaffirmed outperform and overweight ratings, respectively, underscoring positive sentiment toward the company’s integrated pharmacy and healthcare services model.